Year in Review 2024 - Transformative FDA Approvals in Precision Onco…

Oncology 2024 Year in Review

V. Subbiah

ASH 2024 Summary: Highlights in AML, MDS, and ALL

2024 ASH Annual Meeting Insights Hub

T. Badar

Indy Hematology Review 2025: State of the Art 2025 - Emerging Therap…

Indy Hematology Review 2025

R. Birhiray

ASH 2024 Summary: Highlights in Adult ALL and Implications for Pract…

2024 ASH Annual Meeting Insights Hub

R. Cassaday

Indy Hematology Review 2025: Experts Debate the Treatment of ALL in …

Indy Hematology Review 2025

H. Kantarjian

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

Steroid-Refractory GVHD Updates

Roswell Park Comprehensive Cancer Center

S. Holtan

ASH 2024 Summary: Highlights in Ph- ALL

2024 ASH Annual Meeting Insights Hub

F. Haddad

Indy Hematology Review 2025: Experts Debate the Treatment of ALL in …

Indy Hematology Review 2025

R. Stone

Revumenib for KMT2A+ R/R Acute Leukemias - Drug Overview and Clinica…

OncoPharm

J. Bossaer

The Role of Blinatumomab in Frontline B-ALL Treatment

Mark Litzow

Best Practices in Blinatumomab Use for B-Cell ALL: Insights from Cli…

City of Hope

V. Pullarkat

Tandem 2025 Insights: PTCy-Based GVHD Prophylaxis After Mismatched U…

Insights from 2025 Tandem Annual Meeting

M. Al Malki

Recent Updates on Blinatumomab in ALL: FDA Approval in 1L and Incorp…

Sarah Tasian

ASH 2024 Insights: COG AALL1731 - Blinatumomab Added to Chemo in New…

2024 ASH Annual Meeting Insights Hub

S. Gupta

Acute GVHD: Demographics, Diagnosis, Pathophysiology, and Advancemen…

City of Hope

A. Salhotra

Treating Adult B-ALL: CAR-T vs. Bispecifics vs. Monoclonals

Marlise R. Luskin

Updates in ALL: Incorporating Immunotherapy in Frontline Management

Talha Badar